The Enzo Clinical Labs subsidiary of Enzo Biochem, Inc. (NYSE:ENZ) has entered into an agreement to market in its northeast U.S. service area a proprietary early non-invasive prenatal laboratory test (“LDT”) service, MaterniT21 PLUS ™, developed by the Sequenom Laboratories, Inc., subsidiary of Sequenom, Inc. (NASDAQ:SQNM). “The addition of Sequenom Laboratories’ innovative prenatal testing service provides an important complement to our extensive menu of women’s health diagnostic assays, and also is testament to the strong and growing capabilities in the general and rapidly developing area of diagnostics resulting from integration of Enzo’s Life Sciences and Clinical Labs,” said Barry Weiner, Enzo President. Mr. Weiner added, “Sequenom Laboratories’ testing service will be of great value to our physician clients and their patients, providing an advanced crucial assay to assess the potential for chromosomal abnormalities early in a pregnancy. It also underscores our Company’s leading independent position in a highly valuable regional market for clinical laboratory services, and our expertise in the development and marketing of high-value esoteric testing that provides an excellent vehicle through which we can offer this, as well as our growing menu of ground breaking diagnostic assays.” Sequenom Laboratories was the first to market a noninvasive prenatal laboratory-developed test for fetal chromosomal abnormalities. The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy, can be used as early as 10 weeks' gestation, and is run exclusively by Sequenom Center for Molecular Medicine, doing business as Sequenom Laboratories Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. About Enzo Biochem Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2013. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.